This webinar will discuss key concepts in maintenance therapy for ovarian cancer, review clinical efficacy and safety data on potential treatment options and identify and address special considerations for monitoring and patient/caregiver education.
Clinicians may find it difficult to determine which single- or multi-agent therapies are most effective for patients with different kidney cancer histologies and risk groups. The NCCN Categories of Preference and Categories of Evidence and Consensus help to stratify the most effective treatment regimens by histology and risk status.
Although the toxicity profiles of the newer molecularly targeted drugs are less focused on blood cells than those of traditional cytotoxic therapies, there are still infectious risks; safety and efficacy can only be guaranteed by multidisciplinary teams that have therapeutic expertise in the pharmacology of oral anti-cancer therapy.
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with RCC.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Pharmacists can play a critical role in patient education, therapy recommendations, and therapy management in palliative care and should be familiar with appropriate pharmacologic interventions for symptom management.
Facebook
X
LinkedIn
Forward
